XORTX Therapeutics Inc. (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announced that its Pharmacokinetics Bridging Study – XRX-OXY-101 – Part 2 showed a significant increase in oral bioavailability of XORTX’s proprietary oxypurinol formulation provided with...
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), a biopharmaceutical company developing novel treatments for dermatological diseases, announced the acceptance of the New Drug Submission (NDS) for roflumilast cream 0.3% (ARQ-151) for the treatment of plaque psoriasis in adults and adolescents, filed by Arcutis Canada Inc., a subsidiary of...
Greenwich LifeSciences, Inc. (NASDAQ: GLSI), a clinical-stage pharmaceutical company, developing immunotherapy to prevent breast cancer recurrence in patients who previously underwent surgery, announced the removal of the clinical hold on the Phase III Flamingo-01 clinical trial by the U.S Food and Drug Administration (FDA). The FDA...
Oyster Point Pharma, Inc. (NASDAQ: OYST) is a commercial-stage biopharmaceutical company creating first-in-class therapies for the treatment of ophthalmic conditions. The Company’s lead product TYRVAYA, (varenicline solution) Nasal Spray 0.03 mg (formerly referred to as OC-01), has become the first and only FDA-approved nasal spray,...
